Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 97 от 100

Активно (без набиране)

Ovarian Tumor Organotypic Slices Cultures for functionAl Drug Testing and Therapy Response Prediction

Ovarian Cancer

Ex vivo organotypic tumor slice cultures (OTSC) have unique characteristics in terms of tissue processing time and the maintenance of original microenvironment. Moreover, drug screening has been successfully performed on OTSC in a clinically meaningful time window. For these reasons, we designed a study to assess the feasibility of establishing OTSC in OC patients and the concordance between ex vivo sensitivity and in vivo treatment response. If proven effective and reliable, OTSC could be introduced into clinical practice as empirical predictor of patients' response to platinum.

Начало: 13.09.2021 Край: 03.08.2026 Възраст: 18–80 г.

Italy Fondazione Policlinico Universitario Agostino Gemelli I NCT06065358

Активно (без набиране) Фаза 1

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Solid Tumor, Adult Non-small Cell Lung Cancer Melanoma

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

Начало: 04.08.2021 Край: 30.03.2029 Възраст: от 18 г. Лечение

Australia, China, France +4 Pierre Fabre Medicament NCT04913285

Активно (без набиране) Фаза 2

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

Non-small Cell Lung Cancer

Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC

Начало: 02.06.2021 Край: 09.12.2024 Възраст: от 18 г. Лечение

Australia, Georgia, United States Effector Therapeutics NCT04622007

Активно (без набиране) Фаза 3

RegoNivo vs Standard of Care Chemotherapy in AGOC

Gastro-Oesophageal Cancer

To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.

Начало: 01.06.2021 Край: 01.06.2026 Възраст: от 18 г. Лечение

Australia, Germany, Italy +5 Australasian Gastro-Intestinal Trials Group NCT04879368

Активно (без набиране)

Breast Fractionation Study - Standard Versus Investigational Fractionation Trial - Nodal Radiation

Breast Cancer Post Mastectomy

The purpose of this study is to investigate the difference in fatigue, quality of life and radiation morbidity between hypofractionated and conventional radiation to the breast, chest wall and regional lymph nodes post mastectomy or lumpectomy

Начало: 01.06.2021 Край: 31.12.2027 Възраст: от 18 г. Лечение

Australia Royal North Shore Hospital NCT04909125

Активно (без набиране) Фаза 3

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Prostate Cancer

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.

Начало: 12.05.2021 Край: 28.08.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Pfizer NCT04821622

Активно (без набиране) Фаза 2

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Head and Neck Cancer Head and Neck Squamous Cell Carcinoma

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Начало: 10.05.2021 Край: 30.06.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Netherlands +5 ALX Oncology Inc. NCT04675333

Активно (без набиране) Фаза 2

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Head and Neck Cancer Head and Neck Squamous Cell Carcinoma

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Начало: 02.04.2021 Край: 30.06.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +6 ALX Oncology Inc. NCT04675294

Активно (без набиране)

Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients

Melanoma Skin Cancer Anxiety and Fear

This randomised controlled trial will investigate the role of melanoma surveillance photography (MSP) in the surveillance of patients at high or ultra-high risk of melanoma. MSP is a comprehensive method of melanoma monitoring which includes total body photography and digital dermoscopy which is performed at prescribed intervals. The study will test whether participants under surveillance with MSP have less unnecessary biopsies (false positives) compared to those without MSP. Participants will be Australian residents with a new diagnosis of primary melanoma, who have multiple naevi and are at high or ultra-high risk of developing melanoma. Participants will be randomised 1:1 to either groups. It is hypothesised that those randomised to surveillance with MSP will have better patient outcomes. Improved diagnostic performance as measured by the number of unnecessary biopsies will be the primary outcome measure.

Начало: 03.03.2021 Край: 01.05.2025 Възраст: от 18 г. Диагностика

Australia Melanoma and Skin Cancer Trials Limited NCT04385732

Активно (без набиране) Фаза 1/2

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

KRAS G12C Mutant Solid Tumors Carcinoma, Non-Small-Cell Lung Carcinoma, Colorectal Cancer of Lung +6

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.

Начало: 24.02.2021 Край: 25.01.2027 Възраст: 18–100 г. Лечение

Australia, Belgium, Canada +12 Novartis Pharmaceuticals NCT04699188

Активно (без набиране) Фаза 3

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Cancer

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.

Начало: 20.10.2020 Край: 26.06.2028 Възраст: от 18 г. Друго

Argentina, Australia, Belarus +33 Bayer NCT04464226

Активно (без набиране) Фаза 1/2

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Non Small Cell Lung Cancer Advanced Solid Tumor Metastatic Melanoma Metastatic Head and Neck Carcinoma +15

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

Начало: 16.09.2020 Край: 31.12.2027 Възраст: от 18 г. Лечение

Australia, United States OncoC4, Inc. NCT04140526

Активно (без набиране) Фаза 1/2

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Advanced Solid Tumors HER2-positive Breast Cancer

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).

Начало: 03.09.2020 Край: 31.07.2027 Възраст: от 18 г. Лечение

Australia, France, Italy +4 Hoffmann-La Roche NCT05593094

Активно (без набиране) Фаза 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Non-Small Cell Lung Cancer Colorectal Cancer Advanced Solid Tumors

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

Начало: 29.07.2020 Край: 31.12.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +14 Genentech, Inc. NCT04449874

Активно (без набиране) Фаза 2

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

Cancer Cancer, Lung Cancer of Lung Mesothelioma +3

The objective of the study is to induce a meaningful progression-free survival benefit in patients with Malign Pleural Mesothelioma (MPM) after progression on first line standard platinum doublet chemotherapy, by treating with nivolumab and ipilimumab with or without UV1 vaccine.

Начало: 04.05.2020 Край: 15.03.2027 Възраст: от 18 г. Лечение

Australia, Denmark, Norway +2 Åslaug Helland NCT04300244

Активно (без набиране) Фаза 3

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Chronic Lymphocytic Leukemia Acute Myeloid Leukemia Multiple Myeloma Non-Hodgkin's Lymphoma +2

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

Начало: 06.09.2019 Край: 01.08.2027 Лечение

Australia, Belgium, Canada +18 AbbVie NCT03844048

Активно (без набиране) Фаза 1/2

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Medullary Thyroid Cancer Infantile Myofibromatosis Infantile Fibrosarcoma Papillary Thyroid Cancer +1

This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.

Начало: 13.06.2019 Край: 01.05.2029 Възраст: 6–21 г. Лечение

Australia, Canada, Denmark +7 Eli Lilly and Company NCT03899792

Активно (без набиране) Фаза 1

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer Advanced Solid Tumors Triple-Negative Breast Cancer (TNBC) Non-small-cell-lung-cancer (NSCLC) +1

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.

Начало: 21.05.2019 Край: 01.03.2026 Възраст: от 18 г. Лечение

Australia, France, Israel +3 AbbVie NCT03893955

Активно (без набиране) Фаза 1

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Neoplasm Malignant Renal Cell Carcinoma Hormone Receptor Positive Breast Carcinoma Metastatic Castration-resistant Prostate Cancer +1

This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

Начало: 20.03.2019 Край: 31.05.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Czechia +7 Exelixis NCT03845166

Активно (без набиране) Фаза 1/2

Durvalumab and Tremelimumab for Pediatric Malignancies

Pediatric Cancer Solid Tumor Pediatric Hematological Malignancies

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.

Начало: 07.03.2019 Край: 31.12.2026 Възраст: до 18 г.

France, Germany, Italy +4 AstraZeneca NCT03837899

1 … 95 96 97 98 99 100